Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Revista de enfermeria (Barcelona, Spain)·2018
Same journal

Revista de enfermeria (Barcelona, Spain)·2018
Same journal

Revista de enfermeria (Barcelona, Spain)·2018
Same journal

Revista de enfermeria (Barcelona, Spain)·2018
Same journal

Revista de enfermeria (Barcelona, Spain)·2018
Same journal

Revista de enfermeria (Barcelona, Spain)·2018
See all related articles

Related Experiment Video

Updated: May 30, 2026

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

[Hypoglycemia].

A Boltańa Lorenzo1, R Insa Soria

  • 1Servicio de Endocrinología y Nutrición, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona.

Revista De Enfermeria (Barcelona, Spain)
|July 23, 2011
PubMed
Summary
This summary is machine-generated.

Hypoglycemia, a common complication for diabetes patients on insulin, increases with better blood sugar control. Fear of these episodes hinders optimal diabetes treatment and impacts quality of life.

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Experiment Videos

Last Updated: May 30, 2026

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Area of Science:

  • Endocrinology and Metabolism
  • Diabetes Mellitus Research

Context:

  • Hypoglycemia is a frequent acute complication in diabetes mellitus, particularly for patients using insulin or certain oral hypoglycemic agents.
  • Improved metabolic control (reduced HbA1c) lowers chronic diabetes complications but increases hypoglycemia risk, especially with aggressive therapy.

Purpose:

  • To highlight the challenges in optimizing diabetes treatment due to the increased incidence of hypoglycemia.
  • To underscore the impact of hypoglycemia fear on patient quality of life and treatment adherence.

Summary:

  • Aggressive glycemic control in diabetes, while reducing chronic complications, leads to a higher incidence of hypoglycemia.
  • Despite advancements in diabetes medications, replicating endogenous insulin secretion remains difficult, contributing to hypoglycemia fears.
  • Patient apprehension regarding hypoglycemic episodes is a significant barrier to achieving optimal diabetes management and improving quality of life.

Impact:

  • Addresses the critical balance between glycemic control and hypoglycemia prevention in diabetes management.
  • Emphasizes the need for strategies to mitigate hypoglycemia risk and alleviate patient fear.
  • Informs clinical practice and patient education regarding the management of diabetes and its acute complications.